Download PDF
Semin Neurol 2016; 36(04): 373-381
DOI: 10.1055/s-0036-1585454
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV

Leah T. Le
1   Department of Neurology, Yale University, New Haven, Connecticut
,
Serena S. Spudich
1   Department of Neurology, Yale University, New Haven, Connecticut
› Author Affiliations
Further Information

Publication History

Publication Date:
19 September 2016 (online)

    Permissions and Reprints

Abstract

Since the advent of combination antiretroviral therapy (cART), HIV has transformed from a fatal disease to a chronic illness that often presents with milder central nervous system (CNS) symptoms laced with related confounders. The immune recovery associated with access to cART has led to a new spectrum of immune-mediated presentations of infection, phenotypically distinct from the conditions observed in advanced disease.

HIV-associated neurocognitive disorder (HAND) entails a categorized continuum of disorders reflecting an array of clinical presentation, outcome, and increasing level of severity: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD). HAND is defined through an assessment of neurocognitive abilities and functional performance. Progressive neurologic symptoms detected in patients on cART with detectable CSF viral load and a suppressed plasma viral load, or CSF viral load 1 log10 greater than low detectable plasma viral load, characterize a phenomenon termed symptomatic CSF “escape.” CD8+ T-cell encephalitis, possibly a form of CNS immune reconstitution inflammatory syndrome, resembles CNS “escape” as it presents in patients despite viral suppression with cART. Cerebral toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy, are AIDS defining conditions with associated high mortality risk. Cerebral toxoplasmosis and cryptococcal meningitis typically manifest in immunosuppressed patients (<200 CD4+ T-cells/μL), while PML can occur in patients with higher CD4+ T-cell counts.

Neurologic conditions are increasingly interconnected with chronic diseases, and classic opportunistic infections may have altered phenotypes in the cART era. However, there exist promising diagnostic methods and therapeutic approaches, as well as associated pitfalls in diagnosis and treatment.

Keywords

HIV/AIDS - HAND - CNS escape - CD8+ T-cell encephalitis - toxoplasmosis - cryptococcal meningitis - PML
 

  • References

  • 1 UNAIDS. AIDSinfo: Epidemiological Status: World Overview. Available at: http://www.unaids.org/en/dataanalysis/datatools/aidsinfo . Accessed October 12, 2015
    PubMedGoogle Scholar
  • 2 Samji H, Cescon A, Hogg RS , et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE 2013; 8 (12) e81355
    CrossrefPubMedGoogle Scholar
  • 3 d'Arminio Monforte A, Cinque P, Mocroft A , et al; EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55 (3) 320-328
    CrossrefPubMedGoogle Scholar
  • 4 Antinori A, Arendt G, Becker JT , et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69 (18) 1789-1799
    CrossrefPubMedGoogle Scholar
  • 5 Heaton RK, Clifford DB, Franklin Jr DR , et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75 (23) 2087-2096
    CrossrefPubMedGoogle Scholar
  • 6 Simioni S, Cavassini M, Annoni J-M , et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24 (9) 1243-1250
    PubMedGoogle Scholar
  • 7 Bonnet F, Amieva H, Marquant F , et al; S CO3 Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related?. AIDS 2013; 27 (3) 391-400
    CrossrefPubMedGoogle Scholar
  • 8 Castellon SA, Hinkin CH, Myers HF. Neuropsychiatric disturbance is associated with executive dysfunction in HIV-1 infection. J Int Neuropsychol Soc 2000; 6 (3) 336-347
    CrossrefPubMedGoogle Scholar
  • 9 Kamat R, Woods SP, Marcotte TD, Ellis RJ, Grant I ; HIV Neurobehavioral Research Program (HNRP) Group. Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol 2012; 27 (5) 520-531
    CrossrefPubMedGoogle Scholar
  • 10 Heaton RK, Franklin DR, Ellis RJ , et al; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17 (1) 3-16
    CrossrefPubMedGoogle Scholar
  • 11 Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011; 25 (5) 561-575
    CrossrefPubMedGoogle Scholar
  • 12 Wright EJ, Grund B, Robertson K , et al; INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75 (10) 864-873
    CrossrefPubMedGoogle Scholar
  • 13 Becker JT, Kingsley L, Mullen J , et al; Multicenter AIDS Cohort Study. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73 (16) 1292-1299
    CrossrefPubMedGoogle Scholar
  • 14 McCutchan JA, Marquie-Beck JA, Fitzsimons CA , et al; CHARTER Group. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012; 78 (7) 485-492
    CrossrefPubMedGoogle Scholar
  • 15 Spudich SS, Nilsson AC, Lollo ND , et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5 (1) 98
    CrossrefPubMedGoogle Scholar
  • 16 Letendre S, Marquie-Beck J, Capparelli E , et al; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65 (1) 65-70
    CrossrefPubMedGoogle Scholar
  • 17 Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol 2012; 18 (5) 388-399
    CrossrefPubMedGoogle Scholar
  • 18 Arribas JR. Efavirenz: enhancing the gold standard. Int J STD AIDS 2003; 14 (Suppl. 01) 6-14
    PubMedGoogle Scholar
  • 19 Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014; 28 (2) 131-145
    CrossrefPubMedGoogle Scholar
  • 20 Peluso MJ, Meyerhoff DJ, Price RW , et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013; 207 (11) 1703-1712
    CrossrefPubMedGoogle Scholar
  • 21 Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf . Accessed October 8, 2015
    PubMedGoogle Scholar
  • 22 European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV‐infected adults. HIV Medicine. Available at: http://www.eacsociety.org/files/2015_eacsguidelines_8.0-english_revised-20151104.pdf . Accessed November 4, 2015
    PubMedGoogle Scholar
  • 23 Canestri A, Lescure F-X, Jaureguiberry S , et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50 (5) 773-778
    CrossrefPubMedGoogle Scholar
  • 24 Peluso MJ, Ferretti F, Peterson J , et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012; 26 (14) 1765-1774
    CrossrefPubMedGoogle Scholar
  • 25 Gray F, Lescure FX, Adle-Biassette H , et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol 2013; 23 (5) 525-533
    CrossrefPubMedGoogle Scholar
  • 26 Lescure F-X, Moulignier A, Savatovsky J , et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis 2013; 57 (1) 101-108
    CrossrefPubMedGoogle Scholar
  • 27 Djawe K, Buchacz K, Hsu L , et al. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons—San Francisco, 1981-2012. J Infect Dis 2015; 212 (9) 1366-1375
    CrossrefPubMedGoogle Scholar
  • 28 Kodym P, Malý M, Beran O , et al. Incidence, immunological and clinical characteristics of reactivation of latent Toxoplasma gondii infection in HIV-infected patients. Epidemiol Infect 2015; 143 (3) 600-607
    CrossrefPubMedGoogle Scholar
  • 29 Tan IL, Smith BR, von Geldern G, Mateen FJ, McArthur JC. HIV-associated opportunistic infections of the CNS. Lancet Neurol 2012; 11 (7) 605-617
    CrossrefPubMedGoogle Scholar
  • 30 Kumar GG, Mahadevan A, Guruprasad AS , et al. Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging 2010; 31 (6) 1469-1472
    CrossrefPubMedGoogle Scholar
  • 31 Martin-Blondel G, Alvarez M, Delobel P , et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82 (6) 691-693
    CrossrefPubMedGoogle Scholar
  • 32 Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev 2006; (3) CD005420
    PubMedGoogle Scholar
  • 33 Kambugu A, Meya DB, Rhein J , et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46 (11) 1694-1701
    CrossrefPubMedGoogle Scholar
  • 34 Haddow LJ, Colebunders R, Meintjes G , et al; International Network for the Study of HIV-associated IRIS (INSHI). Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10 (11) 791-802
    CrossrefPubMedGoogle Scholar
  • 35 Cohen DB, Zijlstra EE, Mukaka M , et al. Diagnosis of cryptococcal and tuberculous meningitis in a resource-limited African setting. Trop Med Int Health 2010; 15 (8) 910-917
    CrossrefPubMedGoogle Scholar
  • 36 Jarvis JN, Percival A, Bauman S , et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 53 (10) 1019-1023
    CrossrefPubMedGoogle Scholar
  • 37 Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: diagnosis and management update. Curr Trop Med Rep 2015; 2 (2) 90-99
    CrossrefPubMedGoogle Scholar
  • 38 Perfect JR, Dismukes WE, Dromer F , et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50 (3) 291-322
    CrossrefPubMedGoogle Scholar
  • 39 World Health Organization. Rapid advice - diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Available at: http://apps.who.int/iris/bitstream/10665/44786/1/9789241502979_eng.pdf . Accessed October 8, 2015
    PubMedGoogle Scholar
  • 40 Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (3) 291-322
    CrossrefPubMedGoogle Scholar
  • 41 Desalermos A, Kourkoumpetis TK, Mylonakis E. Update on the epidemiology and management of cryptococcal meningitis. Expert Opin Pharmacother 2012; 13 (6) 783-789
    CrossrefPubMedGoogle Scholar
  • 42 Boulware DR, Bonham SC, Meya DB , et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202 (6) 962-970
    CrossrefPubMedGoogle Scholar
  • 43 Cinque P, Bossolasco S, Brambilla AM , et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (Suppl. 01) 73-80
    CrossrefPubMedGoogle Scholar
  • 44 Falcó V, Olmo M, del Saz SV , et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 2008; 49 (1) 26-31
    CrossrefPubMedGoogle Scholar
  • 45 Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9 (10) 625-636
    CrossrefPubMedGoogle Scholar
  • 46 Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66 (2) 262-264
    CrossrefPubMedGoogle Scholar
  • 47 Berger JR, Aksamit AJ, Clifford DB , et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80 (15) 1430-1438
    CrossrefPubMedGoogle Scholar
  • 48 Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4 (1) 59-68
    CrossrefPubMedGoogle Scholar
  • 49 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9 (4) 425-437
    CrossrefPubMedGoogle Scholar
  • 50 Wattjes MP, Richert ND, Killestein J , et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013; 19 (14) 1826-1840
    CrossrefPubMedGoogle Scholar
  • 51 Yousry TA, Pelletier D, Cadavid D , et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72 (5) 779-787
    CrossrefPubMedGoogle Scholar
  • 52 Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H ; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207 , quiz CE1–CE4
    PubMedGoogle Scholar
  • 53 Wiegers K, Schwarck D, Reimer R, Bohn W. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 2008; 375 (1) 73-84
    CrossrefPubMedGoogle Scholar
  • 54 Lima MA, Koralnik IJ. New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol 2005; 11 (Suppl. 03) 52-57
    CrossrefPubMedGoogle Scholar
  • 55 Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A ; Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014; 370 (5) 486-488
    CrossrefPubMedGoogle Scholar
  • 56 Stork L, Brück W, Bar-Or A, Metz I. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol 2015; 129 (3) 467-468
    CrossrefPubMedGoogle Scholar
  • 57 Brickelmaier M, Lugovskoy A, Kartikeyan R , et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53 (5) 1840-1849
    CrossrefPubMedGoogle Scholar
  • 58 Tan CS, Bord E, Broge Jr TA , et al. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr 2012; 60 (3) 244-248
    CrossrefPubMedGoogle Scholar
  • 59 Yamamoto K, Watanabe K, Kikuchi Y, Oka S, Gatanaga H. Long-term functional prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy in the era of combination ART. AIDS Patient Care STDS 2015; 29 (1) 1-3
    CrossrefPubMedGoogle Scholar
  • 60 De Luca A, Ammassari A, Pezzotti P , et al; Gesida 9/99, IRINA, ACTG 363 Study Groups. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22 (14) 1759-1767
    CrossrefPubMedGoogle Scholar